US 11,719,699 B2
Antibodies, compositions, and immunohistochemistry methods for detecting C4.4a
Fernando Jose Rebelo do Couto, Pleasanton, CA (US); Zhiming Liao, Livermore, CA (US); and Yifei Zhu, San Jose, CA (US)
Assigned to Ventana Medical Systems, Inc., Tucson, AZ (US)
Filed by Ventana Medical Systems, Inc., Tucson, AZ (US)
Filed on Feb. 5, 2021, as Appl. No. 17/248,767.
Application 17/248,767 is a division of application No. 15/782,804, filed on Oct. 12, 2017, granted, now 10,948,493.
Application 15/782,804 is a continuation of application No. PCT/EP2016/058135, filed on Apr. 13, 2016.
Claims priority of provisional application 62/149,239, filed on Apr. 17, 2015.
Prior Publication US 2021/0164985 A1, Jun. 3, 2021
Int. Cl. G01N 33/574 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); G01N 1/30 (2006.01)
CPC G01N 33/57492 (2013.01) [C07K 16/28 (2013.01); C07K 16/30 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); G01N 1/30 (2013.01)] 15 Claims
 
1. A monoclonal C4.4a antibody specific for an epitope within a uPAR-like domain 1 within a human C4.4a protein, said monoclonal C4.4a antibody comprising a heavy chain variable region comprising heavy chain complementarity determining regions H-CDR1, H-CDR2, and H-CDR3, wherein H-CDR1 comprises SEQ ID NO: 39, H-CDR2 comprises SEQ ID NO: 41, and H-CDR3 comprises SEQ ID NO: 43, and further comprising a light chain variable region comprising light chain complementarity determining regions L-CDR1, L-CDR2, and L-CDR3, wherein L-CDR1 comprises SEQ ID NO: 47, L-CDR2 comprises SEQ ID NO: 49, and L-CDR3 comprises SEQ ID NO: 51.